PedAM
Pediatric Disease Annotations & Medicines
| Disease | thrombocytopenia |
| Symptom | C0019189|chronic hepatitis |
| Sentences | 21 |
| PubMedID- 24653754 | In november 2012, the us food and drug administration (fda) approved eltrombopag (promacta), an oral thrombopoietin agonist, for treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of ifn-based therapy. |
| PubMedID- 24128106 | Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis c: two case reports. |
| PubMedID- 24621321 | We report a case of severe thrombocytopenia that developed in a patient with chronic hepatitis c treated with pegylated interferon combined with ribavirin in spite of having the inosine triphosphatase-cc genotype. |
| PubMedID- 21188328 | Background and aims: thrombocytopenia in patients with chronic hepatitis c may be the result of several factors: bone marrow inhibition, the decrease of liver thrombopoietin production and an autoimmune mechanism. |
| PubMedID- 22312391 | However, thrombocytopenia also occurs in patients with chronic hepatitis c without cirrhosis. |
| PubMedID- 24731162 | Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis c patients with thrombocytopenia and advanced fibrosis. |
| PubMedID- 20731135 | This article represented a modern view on the problem of thrombocytopenia in patients with chronic hepatitis c, including it's role as an adverse event of antiviral therapy. |
| PubMedID- 20796207 | Epidemiology of thrombocytopenia in patients with chronic hepatitis c: more than meets the eye. |
| PubMedID- 24714308 | Another recent study concluded that anti-p antibodies contribute to thrombocytopenia associated with chronic hepatitis c virus infection . |
| PubMedID- 24304453 | thrombocytopenia in patients with chronic hepatitis c may represent an obstacle for the initiation of antiviral treatment. |
| PubMedID- 20796208 | Prevalence of thrombocytopenia among patients with chronic hepatitis c: a systematic review. |
| PubMedID- 26322297 | Currently, eltrombopag is fda approved for the treatment of thrombocytopenia in chronic hepatitis c, and most recently received approval for the treatment of severe aplastic anemia. |
| PubMedID- 25331767 | Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis c. |
| PubMedID- 22327815 | Causes of thrombocytopenia in chronic hepatitis c viral infection. |
| PubMedID- 25728497 | Background: there are many potential causes of thrombocytopenia in patients with chronic hepatitis c (chc). |
| PubMedID- 23995112 | Eltrombopag is effective for the treatment of chronic hepatitis with thrombocytopenia, and portal vein thrombosis at this time has rarely been reported. |
| PubMedID- PMC4034027 | Recent reports suggest that certain polymorphisms in type i ifn signaling molecules are associated with ifn-induced neutropenia and thrombocytopenia in patients with chronic hepatitis c. ifnγ binds to a cell-surface receptor composed of two transmembrane polypeptides ifgr1 and ifgr2 resulting in activation of the janus kinases jak1 and jak2, phosphorylation of stat1, formation of stat1 homodimers, and activation of a specific set of genes that encode the effector molecules responsible for mediating its biological activity. |
| PubMedID- 19689996 | thrombocytopenia in patients with chronic hepatitis c: a possible role of hcv on platelet progenitor cell maturation. |
| PubMedID- 25764686 | thrombocytopenia in patients with chronic hepatitis c represents an obstacle for the initiation of antiviral treatment. |
| PubMedID- 20720351 | A case of severe thrombocytopenia in a patient with chronic hepatitis c caused by a single administration of pegylated interferon alpha 2a subsequent to 48 weeks of pegylated interferon alpha 2b plus ribavirin therapy. |
| PubMedID- 22708981 | Mechanism of thrombocytopenia in chronic hepatitis c as evaluated by the immature platelet fraction. |
Page: 1